(1 - 10 von 11
)
BioMarker Strategies Raises $1.7 Million, Including Investment by...
www.finanznachrichten.de
BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland...
As Part Of a Company Reorganization, Adhesives Research Debuts...
news.thomasnet.com
As Part Of a Company Reorganization, Adhesives Research Debuts ARmarkTM As One Of Four New Divisions - Adhesives Research, Inc.
Adhesives Research debuts ARclad® as one of four new divisions >...
dnn.aimcal.org
Kären Olson, Adhesives Research president and CEO, named William M. Stratton, III to lead this new division as vice president and general ...
Adhesives Research celebrates fifth anniversary of European...
dnn.aimcal.org
In June of this year, Adhesives Research President and CEO Kären Olson visited Limerick to mark the anniversary with a ceremony, planting ...
Adhesives Research debuts ARcare® as one of four new divisions >...
dnn.aimcal.org
Kären Olson, Adhesives Research president and CEO, named Geoff Bennett to lead this new division as vice president and general manager.
Biomarker Strategies raises $1.7M
www.bmoremedia.com
We also welcome their support of our effort to develop a live tumor cell testing system designed to help oncologists choose the right drug therapy for their cancer patients," says Kären Olson, CEO of BioMarker Strategies. "Even in this challenging economic environment, we found that investors are eager to ...
University of Maryland Entrepreneurship Center Increases...
www.rhsmith.umd.edu
College Park, Md. – August 18, The University of Maryland’s Robert H. Smith School of Business today announced Steven Roth and Kären Olson joined the...
Innovation + Job News
bmoremedia.com
... system designed to help oncologists choose the right drug therapy for their cancer patients," says Kären Olson, CEO of BioMarker Strategies.
Venture investing in Baltimore-area's biotechs jump 16 percent |...
orthospinenews.com
Investors are opening their wallets once again to biotech companies, after shying away from the risky ventures amid a recession.Private biotech companies drew
sortiert nach Relevanz / Datum